Broad Run Investment Management LLC reduced its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 0.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 675,926 shares of the company’s stock after selling 2,300 shares during the quarter. Henry Schein makes up about 1.5% of Broad Run Investment Management LLC’s portfolio, making the stock its 16th biggest holding. Broad Run Investment Management LLC owned 0.43% of Henry Schein worth $47,234,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. FTB Advisors Inc. boosted its stake in shares of Henry Schein by 100.0% during the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock worth $120,000 after acquiring an additional 742 shares during the period. Captrust Financial Advisors bought a new position in shares of Henry Schein during the 4th quarter worth approximately $141,000. Lee Financial Co boosted its stake in shares of Henry Schein by 100.0% during the 3rd quarter. Lee Financial Co now owns 1,756 shares of the company’s stock worth $144,000 after acquiring an additional 878 shares during the period. Advisory Services Network LLC boosted its stake in shares of Henry Schein by 430.1% during the 4th quarter. Advisory Services Network LLC now owns 2,099 shares of the company’s stock worth $147,000 after acquiring an additional 1,703 shares during the period. Finally, Westside Investment Management Inc. boosted its stake in shares of Henry Schein by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 2,000 shares of the company’s stock worth $160,000 after acquiring an additional 1,000 shares during the period. Institutional investors own 98.57% of the company’s stock.
Several brokerages have recently commented on HSIC. Leerink Swann reiterated a “hold” rating on shares of Henry Schein in a research note on Tuesday, February 13th. Evercore ISI started coverage on Henry Schein in a research note on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price target for the company. Zacks Investment Research upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Morgan Stanley downgraded Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price target for the company. in a research note on Wednesday, December 6th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $78.00 price target on shares of Henry Schein in a research note on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. Henry Schein currently has an average rating of “Hold” and an average target price of $82.31.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 20th. The company reported $0.97 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.97. The firm had revenue of $3.32 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Henry Schein had a return on equity of 19.70% and a net margin of 3.26%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.94 EPS. equities research analysts anticipate that Henry Schein, Inc. will post 4.08 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/13/henry-schein-inc-hsic-shares-sold-by-broad-run-investment-management-llc.html.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.